Systemic treatment of advanced lung carcinoid tumors: Show me the data!

Chest

Volumn 143, Issue 4, 2013, Pages 884-886

  Jett, James R ^a   Carr, Laurie L ^a  

^a DEPARTMENT OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; EVEROLIMUS; OCTREOTIDE; PASIREOTIDE; SUNITINIB; TEMOZOLOMIDE;

ADVANCED CANCER; CANCER PATIENT; CARCINOID; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; EDITORIAL; FOLLOW UP; HUMAN; LUNG CANCER; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; QUALITY OF LIFE; STOMATITIS; TREATMENT OUTCOME;

EID: 84876001942     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.12-2455     Document Type: Editorial

References (15)

1. Travis WD. The concept of pulmonary neuroendocrine tumors. In: Travis WD, Brambilla E, Multer-Hermelink HK, Harris CC, eds. Pathology and Genetics of Tumors of the Lung, Pleura, Thymus, and Heart. Lyon, France : IARC Press; 2004 : 19 - 20 .
2. Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas. 2010; 39 (6): 707 - 712 .
3. Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008; 26 (18) : 3063 - 3072 .
4. Rinke A, Müller HH, Schade-Brittinger C, et al; PROMID Study Group. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009; 27 (28) : 4656 - 4663 .
5. Sidéris L, Dubé P, Rinke A. Antitumor effects of somatostatin analogs in neuroendocrine tumors. Oncologist. 2012; 17 (6) : 747 - 755 .
6. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011; 364 (6) : 501 - 513 .
7. Yao JC, Shah MH, Ito T, et al; RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011; 364 (6) : 514 - 523 .
8. Ekeblad S, Sundin A, Janson ET, et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res. 2007; 13 (10) : 2986 - 2991 .
9. Chan JA, Stuart K, Earle CC, et al. Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J Clin Oncol. 2012; 30 (24) : 2963 - 2968 .
10. Yao JC, Phan AT, Chang DZ, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol. 2008; 26 (26) : 4311 - 4318 .
11. Yao JC, Lombard-Bohas C, Baudin E, et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol. 2010; 28 (1) : 69 - 76 .
12. Kulke MH, Siu LL, Tepper JE, et al. Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol. 2011; 29 (7) : 934 - 943 .
13. Pavel ME, Hainsworth JD, Baudin E, et al; RADIANT-2 Study Group. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet. 2011; 378 (9808) : 2005 - 2012 .
14. Fazio N, Granberg D, Grossman A, et al. Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study. Chest. 2013; 143(4): 955 - 962 .
15. National Institutes of Health Clinical Center. 3-Arm trial to evaluate pasireotide LAR/everolimus alone/in combination in patients with lung/thymus NET. NCT01563354. Clinical Trial.gov. Bethesda, MD : National Institutes of Health ; 2012. http ://clinicaltrials.gov/ct2/show/NCT01563354. Accessed October 3, 2012 .